Concert Pharmaceuticals Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Concert Pharmaceuticals stock.
View analyst ratings for Concert Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Concert Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Concert Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Concert Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Concert Pharmaceuticals.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) posted its earnings results on Tuesday, May, 4th. The biotechnology company reported ($0.67) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.66) by $0.01. The biotechnology company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $1.50 million. Concert Pharmaceuticals had a negative net margin of 974.15% and a negative trailing twelve-month return on equity of 59.51%.
View Concert Pharmaceuticals' earnings history.

Concert Pharmaceuticals' stock was trading at $8.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CNCE shares have decreased by 52.0% and is now trading at $4.01.
View which stocks have been most impacted by COVID-19.

4 brokers have issued twelve-month price objectives for Concert Pharmaceuticals' shares. Their forecasts range from $13.00 to $25.00. On average, they anticipate Concert Pharmaceuticals' share price to reach $19.25 in the next twelve months. This suggests a possible upside of 380.0% from the stock's current price.
View analysts' price targets for Concert Pharmaceuticals or view top-rated stocks among Wall Street analysts.

1 employees have rated Concert Pharmaceuticals CEO Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among Concert Pharmaceuticals' employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Concert Pharmaceuticals include Magenta Therapeutics (MGTA), Nanobiotix (NBTX), Forte Biosciences (FBRX), Greenwich LifeSciences (GLSI), XBiotech (XBIT), Geron (GERN), Viking Therapeutics (VKTX), Nabriva Therapeutics (NBRV), TherapeuticsMD (TXMD), Molecular Templates (MTEM), Akouos (AKUS), SIGA Technologies (SIGA), MedAvail (MDVL), Landos Biopharma (LABP) and Flexion Therapeutics (FLXN).
View all of CNCE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT) and Intel (INTC).

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Concert Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (9.43%), BlackRock Inc. (7.23%), Ingalls & Snyder LLC (4.52%), Dimensional Fund Advisors LP (3.13%), Millennium Management LLC (3.13%) and Renaissance Technologies LLC (2.87%). Company insiders that own Concert Pharmaceuticals stock include Heek Christi Van, Jeffrey A Munsie, Nancy Stuart, Peter Barton Hutt, Roger D Tung and Thomas G Auchincloss.
View institutional ownership trends for Concert Pharmaceuticals.

CNCE stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Northern Trust Corp, Man Group plc, Russell Investments Group Ltd., Public Employees Retirement System of Ohio, Nuveen Asset Management LLC, and The Manufacturers Life Insurance Company. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include Jeffrey A Munsie, Nancy Stuart, and Roger D Tung.
View insider buying and selling activity for Concert Pharmaceuticals or view top insider-selling stocks.

CNCE stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Acadian Asset Management LLC, Renaissance Technologies LLC, Geode Capital Management LLC, Assenagon Asset Management S.A., BlackRock Inc., Millennium Management LLC, and Ingalls & Snyder LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van, and Thomas G Auchincloss.
View insider buying and selling activity for Concert Pharmaceuticals or or view top insider-buying stocks.

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CNCE stock can currently be purchased for approximately $4.01.

Concert Pharmaceuticals has a market capitalization of $129.02 million and generates $7.90 million in revenue each year. The biotechnology company earns $-74,770,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

Concert Pharmaceuticals employs 71 workers across the globe.

The official website for Concert Pharmaceuticals is www.concertpharma.com.

Concert Pharmaceuticals is headquartered at 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421.

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]